HS-20117
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-20117 is one of 128 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 3.
4
Indications
5
Total Trials
5
Active Trials
127
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Alecensa
RochePhase 3
Libtayo
RegeneronPhase 3
Enlonstobart
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
HS-20117
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-20117. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details